n a potentially significant policy shift, the Food and Drug Administration plans to stop redacting portions of the resumes submitted by scientific and medical experts who serve on its advisory committees.

The change comes in response to a lawsuit that was filed last year by Public Citizen, a consumer advocacy group, which argued the redactions were unlawful and robbed the public of the opportunity to understand the extent to which any of the expert advisors may have conflicts.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

Recommended Stories

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.